Phase 1 study demonstrates antitumor activity of rezatapopt in TP53 Y220C-mutated tumors, suggesting potential for treatment.
In this phase 1 study involving heavily pretreated patients, the most common adverse events associated with rezatapopt were nausea and vomiting. Antitumor activity occurred across multiple tumor types, providing proof of concept for p53 reactivation. (Funded by PMV Pharmaceuticals; PYNNACLE ClinicalTrials.gov number, NCT04585750.).
No takes yet. Share an insight, caveat, or question.
Dumbrava et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: